KGKamlesh Guleria

Kamlesh Guleria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kamlesh Guleria has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Vasudha Sambyal

    Department of Human Genetics, Guru Nanak Dev University, Amritsar, India

    25 shared publications
  • Manjit Singh Uppal

    Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India

    22 shared publications
  • Meena Sudan

    Department of Radiotherapy, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India

    19 shared publications
  • Mridu Manjari

    Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India

    13 shared publications
  • Neeti Rajan Singh

    Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, India

    13 shared publications
  • Vasudha Sambyal

    Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University, Amritsar, India

    9 shared publications

Latest Publications

  • Association of SIRT1 rs12778366 (T > C) polymorphism with reduced esophageal cancer risk: a case–control study from North India”

    by Jagmohan Singh Bali, Vasudha Sambyal, Sanjana Mehrotra, Kamlesh Guleria, Manjit Singh Uppal, Mridu Manjari, Meena Sudan

    Purpose The protein histone deacetylase silent mating-type information regulator 2 homolog 1 (SIRT1) expression has been linked to cancer prognosis. However, reports evaluating the impact of SIRT1 polymorphisms on esophageal cancer (EC) risk or prognosis are limited. The present study aimed to assess the association between SIRT1 rs12778366 polymorphism and esophageal cancer. Materials and methods The SIRT1 rs12778366 polymorphism was evaluated by PCR-RFLP method in 244 EC patients and 244 healthy controls from Punjab, India. Odds ratios with 95% confidence intervals were used to assess the association of rs12778366 with EC risk. Results The CC genotype (OR = 0.34, 95% CI: 0.12–0.97, p = 0.04) and the C allele (OR = 0.66, 95% CI: 0.47–0.92, p = 0.01) of the SIRT1 rs12778366 polymorphism were significantly associated with a reduced risk of esophageal cancer. Conclusion Previous studies have linked the SIRT1 rs12778366 polymorphism to susceptibility in breast, colorectal, and pituitary tumors, but its role in esophageal cancer has been minimally explored. In the present study, the CC genotype and C allele of SIRT1 rs12778366 were associated with a reduced risk of esophageal cancer in a North Indian population.

  • Open Access

    VEGF and HIF1A polymorphisms and infertility risk in North-West Indians: a case- control study

    by Vasudha Sambyal, Deepanshi Mahajan, Kamlesh Guleria

    Background: Impaired angiogenesis and hypoxia may be involved in infertility, a serious reproductive disorder. VEGF and HIF1A regulate these processes; therefore, genetic variants in these genes serve as candidates for the assessment of infertility risk. The aim of the study was to investigate the association of three VEGF promoter [− 2578C/A (rs699947), − 2549I/D (rs35569394), − 460 T/C (rs833061)] and three HIF1A exonic [g.C1772T (rs11549465), g.G1790A (rs11549467) and g.C111A] polymorphisms with infertility risk in patients from Punjab, North India. Methods: In this case–control study, 193 clinically confirmed infertile patients and 213 age and gender matched healthy controls were investigated. VEGF − 2578C/A, − 460 T/C, HIF1A g.C1772T, g.G1790A and g.C111A polymorphisms were genotyped using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR–RFLP) whereas genotyping of VEGF-2549I/D polymorphism was done using the direct-PCR. Results: VEGF-2549II genotype and I allele, VEGF-2578AA genotype and VEGF-460CC genotypes were significantly associated with increased risk to infertility. Analysis of the data under different genetic models revealed a significantly increased risk under co-dominant (p = 0.02), recessive (p = 0.02) and log additive model (p = 0.03) for VEGF-2549I/D polymorphism whereas VEGF-2578C/A polymorphism was associated with increased risk under co-dominant (p = 0.03) and recessive (p = 0.03) genetic models. VEGF-460 T/C polymorphism was associated with increased risk under co-dominant (p = 0.04) and recessive model (p = 0.04) only. For HIF1A g.G1790A and HIF1A g.C111A polymorphisms, all the patients and controls had GG and CC genotypes respectively. There was no significant difference in the genotype frequency between patients and controls for HIF1A g.C1772T polymorphism. Conclusion: This study suggests that VEGF − 2578C/A, − 2549I/D and − 460 T/C polymorphisms were associated with increased risk of infertility in the patients from Punjab, North India.


  • Open Access

    Correlation of VEGF +405C/G Polymorphism with Gastrointestinal Tract Cancers Risk: An Updated Meta-Analysis

    by Sukhpreet Kaur Walia, Vasudha Sambyal, Kamlesh Guleria

    Background: The functional polymorphisms of VEGF can affect different cellular processes and play a major role in angiogenesis and tumor development. Several case-control studies have explored the association of VEGF +405C/G polymorphism with GIT cancer risk, however, the results were inconsistent. Therefore, the meta-analysis was conducted to clarify the association. Methods: Based on the inclusion and exclusion criteria, relevant data were extracted from PubMed, Google Scholar, Web of Science and Science Direct. Twenty three studies comprising 5,656 cases and 6,319 healthy controls were included in the present meta-analysis and the data was analysed by using online MetaGenyo software. Results: In the present study, no significant association was found in any of the genetic models in overall analysis as well as when data was stratified according to the ethnicity (p>0.05). After performing sub-group analysis on the basis of cancer type, significant association was found with increased risk of developing esophageal cancer under allele contrast, recessive, GG vs. CC and GG vs. GC models (p<0.05). Under overdominant model, VEGF +405C/G polymorphism was significantly associated with decreased risk of developing esophageal cancer (p=0.017) and GG vs. GC model showed a significant association with the risk of developing colorectal cancer (p=0.047) and pancreatic cancer (p=0.010). However, GC vs. CC model showed that VEGF +405C/G polymorphism was significantly associated with reduced risk of pancreatic cancer (p=0.039). Conclusion: The present updated meta-analysis suggested that VEGF +405C/G polymorphism may serve as a biomarker for determining an individual’s risk of esophageal, colorectal and pancreatic cancer.

  • Open Access

    Association of Insertion/Deletion Polymorphisms of MDM2, MCP-1 and VEGF with Esophageal Cancer Risk in North-West Indians: A Case - Control Study

    by Deepanshi Mahajan, Vasudha Sambyal, Manjit Singh Uppal, Meena Sudan, Kamlesh Guleria

    Background: The carcinogenesis process in esophageal cancer (EC), a highly heterogeneous and multifaceted disease, is influenced by both tumor angiogenesis and chronic inflammation pathways. Genetic variants in these pathways may affect the progression and development of EC, ultimately contributing to different susceptibilities to cancer among individuals. Methods: In this study, a total of 536 subjects were recruited, including 260 EC patients and 276 healthy individuals. The DNA was isolated from the blood samples of the participants using the standard phenol-chloroform method. The three insertion/deletion (ins/del) polymorphisms (VEGF-2549 18bp I/D, MDM2 40bp I/D, and MCP-1 14bp I/D) were screened using the Direct-polymerase chain reaction (PCR) genotyping method. The role of gene-environment interactions on EC risk was assessed using the Multifactor Dimensionality Reduction (MDR) software (version 3.0.2). Results: It was observed that the individuals carrying the II genotype and I allele of the VEGF-2549 18bp I/D polymorphism, as well as the carriers of the ID and DD genotypes and D allele of the MCP-1 14bp I/D polymorphism had a higher risk of developing EC. No association between the MDM2 40bp I/D polymorphism and EC risk was reported in this study. Genotype combination analysis revealed an increased EC risk in the carriers of the II-II-II genotype combination of the VEGF-2549 18bp I/D, MDM2 40bp I/D, and MCP-1 14bp I/D polymorphisms compared to those with other genotype combinations. The gene-environment interaction analysis also indicated a strong interaction between lifestyle factors and genetic polymorphisms in influencing EC risk. Conclusion: The present study concluded that the VEGF-2549 18bp I/D and MCP-1 14bp I/D variants were associated with EC risk in the North-west Indians.


  • Open Access

    Association of VEGF promoter polymorphisms with gastrointestinal tract cancer risk and therapy response: a systematic review

    by Deepanshi Mahajan, Vasudha Sambyal, Kamlesh Guleria

    Background: Gastrointestinal tract (GIT) cancers are the most lethal cancers with a high incidence and poor prognosis. Vascular endothelial growth factor (VEGF) glycoprotein plays an essential role in tumour neovascularization, especially in cancers of the gastrointestinal tract. There are numerous functional polymorphisms reported in the VEGF which lead to either upregulation or downregulation of VEGF expression. Objective: The present review focuses on the role of VEGF functional polymorphisms in influencing the risk and prognosis of various GIT cancers. Method of study: This systematic review was done by Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, and Participant, Intervention, Comparison, Outcomes and Studies (PICOS) criteria were followed for designing the study. A total of 183 articles were retrieved from Google Scholar, PubMed and ScienceDirect using various keywords. After full-text evaluation and applying the literature selection criteria, 108 articles were selected in the review. The role of VEGF promoter polymorphisms in influencing various transcription factor binding sites (TFBS) in the VEGF promoter was studied by performing an in silico analysis. Results: This review article summarized the findings of the studies on the associations of VEGF promoter polymorphisms with various GIT cancers. The effect of the VEGF promoter polymorphisms on cancer risk and prognosis varied between different ethnicities and different GIT cancers. The in silico analysis revealed that the VEGF polymorphisms alter the TFBS, leading to attenuation of the functional activity of the transcription factors which might have importance in the GIT cancer development. Conclusion: VEGF is as an important biomarker for studying the disease susceptibility, progression and prognosis in GIT cancers.


  • Open Access

    Association of VEGFR1, VEGFR2 and VEGFR3 polymorphisms with esophageal cancer risk: a case–control study

    by Sukhpreet Kaur Walia, Vasudha Sambyal, Meena Sudan, Manjit Singh Uppal, Kamlesh Guleria

    Background: Esophageal cancer is the eleventh most common cancer and is the seventh leading cause of mortality worldwide. Vascular endothelial growth factor (VEGF) and its receptors pathway are a key regulator of angiogenesis and play an important role in carcinogenesis. The aim of current study was to evaluate the association of five VEGFR polymorphisms with esophageal cancer risk in patients from Punjab, North-west India. Methods: This case–control study included 310 esophageal cancer patients and 325 age and gender matched healthy controls. VEGFR1-710C/T, VEGFR2-604 T/C (rs2071559), VEGFR2 1192 G/A (rs2305948), VEGFR2 1719A/T (rs1870377) and VEGFR3 (rs72816988) polymorphisms were genotyped by using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) method. Restriction digestion products were analyzed on 2.4% agarose gel and genotype was assigned to each sample on the basis of fragments obtained after digestion. Randomly 10% samples were repeated by Sanger sequencing to revalidate the results. Results: There was a significant association of CT genotype (OR = 0.28; 95%CI, 0.10–0.76; p = 0.01) and T allele (OR = 0.28; 95%CI, 0.10–0.77; p = 0.01) of VEGFR1-710C/T polymorphism with decreased risk of esophageal cancer. TC genotype of VEGFR2-604 T/C (OR = 0.66; 95%CI, 0.44–0.97; p = 0.03) and GA genotype of VEGFR2 1192G/A (OR = 0.54; 95%CI, 0.31–0.95; p = 0.03) polymorphisms were significantly associated with decreased risk of esophageal cancer. There was no significant difference in allele and genotype frequency of VEGFR2 1719A/T and VEGFR3 (rs72816988) polymorphisms between esophageal cancer patients and controls (p > 0.05). Haplotype analysis revealed that haplotype C-604A1719A1192 was significantly associated with the decreased esophageal cancer risk (OR = 0.44; 95%CI, 0.23–0.84; p = 0.01). Conclusion: VEGFR1-710C/T, VEGFR2-604 T/C and VEGFR2 1192G/A polymorphisms were associated with the decreased risk of esophageal cancer in patients from Punjab, North-west India. Graphical


  • Open Access

    Association of VEGFA polymorphisms with the risk of oesophageal cancer in Punjab, India: A case-control study

    by Kamlesh Guleria, Vasudha Sambyal, Sukhpreet Kaur Walia, Meena Sudan, Manjit Singh Uppal

    Background & objectives: Vascular endothelial growth factor (VEGF) is one of the most important angiogenic factors which stimulates tumour progression induction of endothelial cell migration and division, inhibition of the apoptosis of endothelial cells, induction of serine protease activity and enhancement of vascular permeability. This study aimed to investigate the correlation of VEGF+405G/C,-7C/T and+936C/T polymorphisms with oesophageal cancer risk. Methods: DNA samples of 464 subjects (231 sporadic oesophageal cancer affected individuals and 233 controls) were genotyped forVEGF+936C/T,+405G/C and-7C/T polymorphisms. VEGF+936C/T and +405G/C polymorphisms were genotyped by PCR-RFLP method whereas VEGF-7C/T polymorphism was genotyped using Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Results: CT genotype of VEGF-7C/T polymorphism was significantly associated with reduced risk of oesophageal cancer. VEGF-7C/T polymorphism was significantly associated with reduced risk of oesophageal cancer underdominant, co-dominant, over dominant and log-additive genetic models in total patients and in the female group. C+936G+405T-7 haplotype was significantly associated with decreased risk (P=0.01)of oesophageal cancer in total patients and also in the male group (P=0.02). Interpretation & conclusions: In future, replication of the findings of the present study in a larger sample from different ethnic groups, along with functional analysis, may be insightful for the role of VEGFA polymorphisms in the pathogenesis of oesophageal cancer. Identification of the correlation of VEGF variants with specific therapy in oesophageal cancer may help in better selection of patients and monitoring treatment response in VEGF-therapy.


  • Open Access

    Association of VEGF-2549I/D promoter polymorphism with gastrointestinal tract cancer risk: a meta-analysis

    by Deepanshi Mahajan, Vasudha Sambyal, Kamlesh Guleria

    Background: Gastrointestinal tract (GIT) cancers are complex disorders affecting millions of people worldwide. The vascular endothelial growth factor (VEGF) helps in the development of different GIT cancers by promoting abnormal angiogenesis in cancer cells. The role of VEGF-2549I/D polymorphism in influencing GIT cancer susceptibility has been studied in different populations with inconclusive results. Therefore, the relationship between VEGF-2549I/D polymorphism with GIT susceptibility was studied by performing a meta-analysis study. Methods: Various online databases were used for identifying the articles. Based on study selection criteria, five studies on different GIT cancers including 1178 patients and 1520 controls were included in the meta-analysis. The accuracy of the study results was determined by performing a trial sequential analysis. Results: In this study, the VEGF-2549I/D polymorphism did not influence the GIT cancer susceptibility in the overall analysis as well as when stratified according to ethnicity (p > 0.05). Stratification of all the studies based on the different GIT cancers reported an increased susceptibility to gastric cancer under different genetic models including allele contrast (OR = 1.67, CI = 1.294–2.157, p = 0.00008), recessive (OR = 1.68, CI = 1.056–2.660, p = 0.029), dominant (OR = 2.49, CI = 1.617–3.823, p = 0.00003), over-dominant (OR = 1.52, CI = 1.055–2.177, p = 0.025), II vs DD (OR = 2.97, CI = 1.692–5.208, p = 0.00015) and ID vs DD model (OR = 2.35, CI = 1.501–3.669, p = 0.00018). Conclusion: There was no relationship between VEGF-2549I/D promoter polymorphism and GIT cancer susceptibility in the overall population and also in different ethnic groups. Stratification analysis revealed higher susceptibility towards gastric cancer development with VEGF-2549I/D polymorphism.

  • VEGF -2578C/A, -460T/C Polymorphisms and Gastrointestinal Tract Cancer Risk: An Updated Meta-Analysis

    by Deepanshi Mahajan, Vasudha Sambyal, Manjit Singh Uppal, Meena Sudan, Kamlesh Guleria

    Functional polymorphisms in the vascular endothelial growth factor (VEGF) alter the susceptibility toward different gastrointestinal tract (GIT) cancers. In this study, we explored the association ...